• 1
    American Cancer Society. Cancer facts and figures, 2005. Atlanta, GA: American Cancer Society; 2005. Available at URL: [accessed April 2005].
  • 2
    Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics. 2003; 21: 383396.
  • 3
    Friedlander ML, Tattersall MH. Counting the costs of cancer therapy. Eur J Cancer Clin Oncol. 1982; 18: 12371241.
  • 4
    Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care. 1991; 29: 4049.
  • 5
    Mor V, Malin M, Allen S. Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst. 1994; 16: 191197.
  • 6
    Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995; 87: 417426.
  • 7
    Will BP, Le Petit C, Berthelot JM, Tomiak EM, Verma S, Evans WK. Diagnostic and therapeutic approaches for non metastatic breast cancer in Canada, and their associated costs. Br J Cancer. 1999; 79: 14281436.
  • 8
    Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 10811092.
  • 9
    ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 6062.
  • 10
    BIG 1-98 Collaborative Group. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIT 1-98: a prospective randomized double-blind Phase III study [abstract]. Breast. 2005; 14(Suppl 1): S4.
  • 11
    Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 12
    Deyo RA, Cherkin CD, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613619.
  • 13
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 14511467.
  • 14
    U.S. Department of Labor. Bureau of Labor Statistics Consumer Price Index for All Urban Consumers. 2005: U.S. city average. Item: medical care. Base period: 1982-84 = 100. Washington, DC: U.S. Department of Labor, 2005. Available at URL: [accessed April 2005].
  • 15
    Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004; 171: 22502254.
  • 16
    Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies—report of the ISPOR Task Force on Retrospective Databases. Value Health. 2003; 6: 9097.
  • 17
    Smith I. Adjuvant treatment for early breast cancer. Ann Oncol. 2005; 16(Suppl 2): ii182ii187.
  • 18
    Bonneterre J, Bercez C, Bonneterre M-E, Lenne X, Dervaux B. Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study). Ann Oncol. 2005; 16: 915922.
  • 19
    Locker GY, on behalf of the ATAC Trialists' Group. Cost-utility analysis of anastrozole versus tamoxifen as primary adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare system perspective: the 5-year completed treatment analysis of the ATAC (‘Arimidex,’ Tamoxifen Alone or in Combination) trial [abstract]. Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2004.